Platinum-Resistant Ovarian CancerPhase 1NCT06964009
DT2216
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
8 Phase 1 studies recruiting right now, most recently updated first.
Open the Phase 2 page · a list of only those studies
Triangle is made by Triangle Health, Inc.
Ovary and gynecologic8 studies
Platinum-Resistant Ovarian CancerPhase 1NCT06964009
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
Platinum-Resistant Ovarian CarcinomaPhase 1NCT05225363Papers
Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer
Platinum-Sensitive Recurrent Ovarian and Endometrial CancerPhase 1/2NCT06040970
Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
Stage IVB Cervical CancerPhase 1/2NCT06543576
External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer
Recurrent or Unresectable pMMR Endometrial (Uterine) CancerPhase 1NCT05603910
Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
Cervical Intraepithelial Neoplasia and Invasive Cervical CancerPhase 1NCT06191133
Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma
Platinum-resistant Ovarian CancerPhase 1NCT06321484
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
Recurrent Ovarian CancerPhase 1/2NCT05610735
Combination Therapy for Recurrent Ovarian Cancer